Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123

Completed · Phase 1

Conditions studied: Differentiated Thyroid Cancer

In brief

The purpose of the study is to find out if the small dose of radioiodine, that is used for the dosimetry study on patients with differentiated thyroid cancer, may stun the cancer cells and make the thyroid cancer treatment less effective.

Key facts

Study ID

NCT02278198

Run by

University of Colorado, Denver

People needed

5

Starts

2012-11-30

Expected to finish

2019-09-20

Last updated by the study team

2019-10-24

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must be 21-years-old or greater.
• Patient must be status post near total thyroidectomy for differentiated thyroid cancer without known distant metastases and who are planning to undergo routine remnant thyroid tissue ablation with I-131.
• Patients must qualify for thyroid ablation with I-131.

You may not qualify if…

• Women who are pregnant or breastfeeding.
• Prior bovine TSH use.
• Known metastatic thyroid cancer.
• History of cardiovascular disease that may adversely affect patient participation at the discretion of the primary investigator.
• Patients on hemodialysis.
• Patients with acute serious illnesses at the discretion of the primary investigator.

Where it is running

• Fawn N White — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.